Bosnian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
prostaglandin f 2 alpha/moždani udar
Veza se sprema u međuspremnik
11 rezultati
Dihydrogen phosphate salt of a prostaglandin D2 receptor antagonist
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
FIELD OF THE INVENTION
Large-scale manufacturing of a pharmaceutical composition may pose many challenges to the chemist and chemical engineer. While many of these challenges relate to the handling of large quantities of reagents and control of large-scale reactions, the handling of the final
2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
FIELD OF THE INVENTION
The present invention is directed to pyrimidine compounds, their preparation, pharmaceutical compositions containing these compounds, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of prostaglandin D2
Methods for the use of inhibitors of cytosolic phospholipase A2
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
FIELD OF THE INVENTION
The present invention relates to methods for the use of chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A.sub.2 enzymes (cPLA.sub.2), more particularly including inhibitors of cytosolic phospholipase A.sub.2 alpha
Methods for the use of inhibitors of cytosolic phospholipase A2
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
FIELD OF THE INVENTION
The present invention relates to methods for the use of chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A.sub.2 enzymes (cPLA.sub.2), more particularly including inhibitors of cytosolic phospholipase A.sub.2 alpha
Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
TECHNICAL FIELD
The present invention relates to (1) a carboxylic acid compound represented by formula (I)
##STR00002##
wherein all symbols have the same meanings as follows, salts thereof, solvates thereof, and prodrugs thereof, (2) a process for producing the same, (3) a pharmaceutical composition
Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
TECHNICAL FIELD
The present invention relates to (1) a carboxylic acid compound represented by formula (I)
##STR00002##
wherein all symbols have the same meanings as follows, salts thereof, solvates thereof, and prodrugs thereof,
(2) a process for producing the same,
(3) a pharmaceutical composition
Thromboxane synthetase inhibiting 3-(1-alkenyl) pyridines
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
This invention relates to novel substituted vinyl derivatives which are capable of inhibiting thromboxane A.sub.2 (TXA.sub.2) synthetase specifically.
TXA.sub.2 is one of the arachidonic acid metabolites and is a potent inducer of platelet aggregation and vascular smooth muscle contractions.
Vinyl carboxylic acid derivatives, their production and use as inhibitors of thromboxane synthetase
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
The present invention relates to novel substituted vinylcarboxylic acid derivatives which possess the action to inhibit specifically the thromboxane A.sub.2 (TXA.sub.2) synthetase.
TXA.sub.2 is a metabolite of arachidonic acid and has the platelet aggregating action. Therefore, it has been known
Endogenous repair factor production accelerator
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
TECHNICAL FIELD
The present invention relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (hereinafter referred to as "PG") I2 agonist, EP2 agonist and EP4 agonist.
BACKGROUND ART
Regeneration medical treatment is drawing
Endogeneous repair factor production accelerators
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
TECHNICAL FIELD
The present invention relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (hereinafter referred to as "PG") I2 agonist, EP2 agonist and EP4 agonist.
BACKGROUND ART
Regeneration medical treatment is drawing
Endogeneous repair factor production promoters
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
TECHNICAL FIELD
The present invention relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (hereinafter referred to as "PG") I2 agonist, EP2 agonist and EP4 agonist.
BACKGROUND ART
Regeneration medical treatment is drawing
Najkompletnija baza ljekovitog bilja potpomognuta naukom
- Radi na 55 jezika
- Biljni lijekovi potpomognuti naukom
- Prepoznavanje biljaka po slici
- Interaktivna GPS karta - označite bilje na lokaciji (uskoro)
- Pročitajte naučne publikacije povezane sa vašom pretragom
- Pretražite ljekovito bilje po učincima
- Organizirajte svoja interesovanja i budite u toku sa istraživanjem vijesti, kliničkim ispitivanjima i patentima
Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Sve informacije temelje se na objavljenim naučnim istraživanjima
